EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The molecular history of IDH ‐mutant astrocytomas without adjuvant treatment

Zhi-Feng Shi, Kay Ka-Wai Li iD, Johnny Sheung-Him Kwan, Nellie Yuk-Fei Chung, Sze-Ching Wong, Abby Wai-Yan Chu, Hong Chen, Danny Tat-Ming Chan, Ying Mao, Ho-Keung Ng iD

Brain Pathology · 2025

DOI: 10.1111/bpa.13300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Pathology, 2025. Verfasst von Zhi-Feng Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Astrocytoma, Brain Neoplasms. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypermutation and malignant transformation are potential complications arising from temozolomide treatment of IDH ‐mutant gliomas. However, the natural history of IDH ‐mutant low‐grade gliomas without temozolomide treatment is actually under‐studied. We retrieved retrospectively from our hospitals paired tumors from 19 patients with IDH ‐mutant, 1p19q non‐codeleted Grade 2 astrocytomas where no interim adjuvant treatment with either temozolomide or radiotherapy was given between primary resections and first recurrences. Tissues from multiple recurrences were available from two patients and radiotherapy but not temozolomide was given before the last specimens were resected. We studied the natural molecular history of these low‐grade IDH ‐mutant astrocytomas without pressure of temozolomide with DNA methylation profiling and copy number variation (CNV) analyses, targeted DNA sequencing, TERT p sequencing, FISH for ALT and selected biomarkers. Recurrences were mostly higher grades (15/19 patients) and characterized by new CNVs not present in the primary tumors (17/19 cases). Few novel mutations were identified in recurrences. Tumors from 17/19 (89.5%) patients showed either CDKN2A homozygous deletion, MYC or PDGFRA focal and non‐focal gains at recurrences. There was no case of hypermutation. Phylogenetic trees constructed for tumors for the two patients with multiple recurrences suggested a lack of subclone development in their evolution when under no pressure from temozolomide. In summary, our studies demonstrated, in contrast to the phenomenon of temozolomide‐induced hypermutation, IDH ‐mutant, 1p19q non‐codeleted Grade 2 astrocytomas which had not been treated by temozolomide, acquired new CNVs at tumor recurrences. These findings improve our understanding of the molecular life history of IDH ‐mutant astrocytomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseAstrocytomaBrain NeoplasmsHumansFemaleMaleMiddle AgedAdultMutationAgedRetrospective StudiesTemozolomideDNA Copy Number VariationsNeoplasm Recurrence, LocalYoung AdultDNA Methylation

Stichwörter der Autor:innen

CDKN2AIDH‐mutant astrocytomas without adjuvant treatmentMYC

Substanzen

Isocitrate DehydrogenaseTemozolomideIDH1 protein, humanIDH2 protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
  • Hong Kong and Shanghai Brain Consortium (HSBC), Hong Kong, China.
  • Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China.
  • Hong Kong Genome Institute, Hong Kong Science Park, Shatin, Hong Kong, China.
  • Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
  • Division of Neurosurgery, Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

ORCID-Profile: Kay Ka-Wai Li, Ho-Keung Ng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Shi, Z. F., Li, K. K., Kwan, J. S., Chung, N. Y., Wong, S. C., Chu, A. W., Chen, H., Chan, D. T., Mao, Y., & Ng, H. K. (2025). The molecular history of IDH ‐mutant astrocytomas without adjuvant treatment. Brain Pathology. https://doi.org/10.1111/bpa.13300

Vancouver

Shi ZF, Li KK, Kwan JS, Chung NY, Wong SC, Chu AW, et al. The molecular history of IDH ‐mutant astrocytomas without adjuvant treatment. Brain Pathology. 2025. doi:10.1111/bpa.13300

BibTeX
@article{Shi2025,
  author = {Shi, Zhi-Feng and Li, Kay Ka-Wai and Kwan, Johnny Sheung-Him and Chung, Nellie Yuk-Fei and Wong, Sze-Ching and Chu, Abby Wai-Yan and Chen, Hong and Chan, Danny Tat-Ming and Mao, Ying and Ng, Ho-Keung},
  title = {The molecular history of IDH ‐mutant astrocytomas without adjuvant treatment},
  journal = {Brain Pathology},
  year = {2025},
  doi = {10.1111/bpa.13300}
}
Kostenlos starten →